Clinical Trials

Lymphoma, Mantle-Cell

NCT01424982 2026-04-15

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

88 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04978584 2026-04-15

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

62 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT01661881 2026-04-08

Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma

23 enrolled 8 charts

Lymphoma, Mantle-Cell

NCT03697512 2026-04-08

MALIBU

175 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT05798156 2026-04-08

R-Pola-Glo

125 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05303792 2026-04-07

Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults With B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma

68 enrolled

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT03467867 2026-04-06

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

25 enrolled

Leukemia, Lymphoproliferative Disorders, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02682641 2026-03-27

Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL

Lymphoma, Mantle-Cell

NCT03361852 2026-03-25

Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma

20 enrolled

Lymphoma, Follicular

NCT02446236 2026-03-24

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

27 enrolled 11 charts

Lymphoma, Mantle-Cell

NCT01479842 2026-03-23

Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

48 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04458610 2026-03-20

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

60 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05025800 2026-03-20

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

47 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

NCT00492050 2026-03-11

Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

46 enrolled 10 charts

Waldenstrom Macroglobulinemia

NCT02446457 2026-03-09

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

53 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT02339922 2026-03-05

Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma

33 enrolled 16 charts

Phase EARLY_PHASE1 Active not recruiting

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT05495464 2026-02-27

A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma

22 enrolled

Lymphoma, Lymphoma, Mantle-Cell

NCT01880567 2026-02-19

Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

113 enrolled

Lymphoma, Mantle-Cell

NCT03147612 2026-02-17

Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia

22 enrolled

Blast Crisis, Leukemia, Myeloid, Accelerated Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05551936 2026-02-17

A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma

42 enrolled

Lymphoma, Follicular

NCT02158091 2026-02-13

A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

32 enrolled 11 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03710772 2026-02-11

Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

51 enrolled

Lymphoma, Mantle-Cell

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

30 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04375228 2026-02-06

Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)

8 enrolled

Other solid neoplasm

Immune-related Adverse Events

NCT04624906 2026-02-04

BRAWM

63 enrolled

Waldenstrom Macroglobulinemia

NCT04323956 2026-02-02

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

NCT03943901 2026-01-29

Split-Dose R-CHOP for Older Adults With DLBCL

27 enrolled 11 charts

Lymphoma, Neoplasms, Lymphoma, Large B-Cell, Diffuse

NCT01959698 2026-01-28

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

29 enrolled 19 charts

Lymphoma, Large B-Cell, Diffuse

NCT01446133 2026-01-27

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

120 enrolled

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03808610 2026-01-09

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04843904 2026-01-07

SAVE

40 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04594798 2025-12-17

A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL

39 enrolled

Phase 2/3 Active not recruiting

Lymphoma, B-Cell

NCT01046825 2025-12-10

Mature B-Cell Lymphoma And Leukemia Study III

128 enrolled 12 charts

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin

NCT03620903 2025-12-05

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

53 enrolled

Waldenstrom Macroglobulinemia

NCT05065554 2025-12-05

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

12 enrolled

Waldenstrom Macroglobulinemia, Neuritis

NCT03352765 2025-12-04

A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients

28 enrolled

Phase 3 Active not recruiting

Lymphoma

NCT02390869 2025-12-02

FIL_RENOIR12

128 enrolled

Lymphoma, Follicular, Recurrence

NCT07247383 2025-11-25

Orelabrutinib Plus Low-Dose Radiotherapy Or Rituximab For Ocular Adnexal MALT Lymphoma

39 enrolled

Lymphoma, B-Cell, Marginal Zone

NCT02427620 2025-11-21

Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma

131 enrolled

Lymphoma, Mantle-Cell

NCT04765111 2025-11-10

Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

53 enrolled

Lymphoma, Mantle-Cell

NCT02007044 2025-11-06

Ibrutinib With or Without Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

66 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic

NCT02251548 2025-10-24

iFCR

85 enrolled 17 charts

Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04981912 2025-10-15

Rituximab + High-Dose Methylprednisolone Debulking Prior to Venetoclax for CLL & SLL Patients

4 enrolled 8 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05270057 2025-10-09

LONCA

11 enrolled

Phase 3 Active not recruiting

Burkitt Lymphoma, Lymphoma, B-Cell

NCT04833114 2025-09-30

Pola-R-ICE

306 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04479267 2025-09-29

Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma

8 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04447716 2025-09-15

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

4 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04665765 2025-09-03

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

41 enrolled 12 charts

Lymphoma, Large B-Cell, Diffuse

NCT01810588 2025-09-02

Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation